Mitochondrial Disease Cell Models for Research

Mitochondrial diseases are a heterogeneous group of disorders caused by dysfunction of the mitochondrial respiratory chain, affecting energy production. The estimated prevalence is approximately 1 in 5,000 live births for primary mitochondrial diseases (WHO, 2023). These conditions can manifest at any age, with symptoms ranging from mild exercise intolerance to severe multi-organ failure, often involving the nervous system, muscles, heart, and liver. The clinical burden is substantial, with many patients experiencing progressive disability and reduced quality of life. There is currently no cure, and treatment options are largely supportive, underscoring the urgent need for research into disease mechanisms and therapeutic targets.

Mitochondrial diseases are ideal for mechanistic studies due to their well-defined genetic basis, often involving mutations in mitochondrial DNA (mtDNA) or nuclear genes encoding mitochondrial proteins. The availability of patient-derived cell lines and the ability to generate isogenic models via gene editing enable precise dissection of genotype-phenotype relationships. Key open questions include the role of heteroplasmy (mixed populations of mutant and wild-type mtDNA), tissue-specific vulnerability, and the interplay between mitochondrial dysfunction and cellular signaling pathways. Public datasets, such as those from the Mitochondrial Disease Sequence Data Resource (MSeqDR) and ClinVar, provide valuable genomic information for research.

Mitochondrial dysfunction arises from defects in oxidative phosphorylation (OXPHOS), leading to reduced ATP production, increased reactive oxygen species (ROS), and altered cellular metabolism. Key pathways include:

• • Oxidative phosphorylation (OXPHOS): Defects in any of the five complexes (I-V) impair electron transport and ATP synthesis.
• • Mitochondrial dynamics: Imbalance in fission and fusion affects mitochondrial morphology and function.
• • Mitochondrial quality control: Impaired mitophagy leads to accumulation of damaged mitochondria.
• • Apoptosis: Mitochondrial outer membrane permeabilization triggers cell death, contributing to tissue degeneration.

Common genetic alterations in mitochondrial disease include point mutations and large deletions in mtDNA, as well as mutations in nuclear genes. The table below lists representative genes and their mutation frequencies (based on data from ClinVar and MSeqDR).

Mitochondrial dysfunction affects multiple signaling pathways:

• • AMPK pathway: Activated by low ATP, promotes catabolism and mitochondrial biogenesis.
• • mTOR pathway: Inhibited by mitochondrial stress, affecting cell growth and autophagy.
• • Calcium signaling: Mitochondrial calcium uptake regulates apoptosis and metabolism.
• • ROS signaling: Elevated ROS activate stress-responsive transcription factors like Nrf2 and NF-κB.
• • Integrated stress response (ISR): Mitochondrial stress activates ISR via eIF2α phosphorylation, altering gene expression.

Common cell lines used in mitochondrial disease research include:

Organoids, such as cerebral organoids, offer a more physiologically relevant model for studying neuronal involvement and can be generated from patient-derived induced pluripotent stem cells (iPSCs).

Animal models for mitochondrial disease include:

• • Mitochondrial mutator mice (POLG D257A): Accumulate mtDNA mutations, showing premature aging.
• • Ndufs4 knockout mice: Model Leigh syndrome, with severe neurological symptoms.
• • Ant1 knockout mice: Model mitochondrial myopathy.
• • Zebrafish models: Used for high-throughput drug screening.
• • Patient-derived xenografts (PDX): Limited for mitochondrial disease due to the metabolic nature, but used for cancer-related mitochondrial defects.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mitochondrial or nuclear gene modifications. For example, a knockout of the nuclear gene NDUFS4 in HEK293 cells recapitulates Complex I deficiency, while a knock-in of the mtDNA mutation m.3243A>G in cybrids models MELAS syndrome. These sequence-verified models are commercially available and accelerate research by providing consistent, reproducible systems. They are essential for studying disease mechanisms, validating therapeutic targets, and screening drug candidates.

Gene-edited cell lines are used to validate the functional impact of genetic variants. For example, knocking out MFN2 in HeLa cells demonstrates its role in mitochondrial fusion and cellular respiration. Similarly, introducing a patient-specific mutation into a control cell line via CRISPR knock-in allows direct comparison of mutant and wild-type phenotypes, confirming causality.

Isogenic pairs (wild-type vs. mutant) are used in high-throughput screens to identify compounds that selectively target mutant cells. For instance, screening against cells with a Complex I deficiency can identify drugs that rescue ATP production or reduce ROS. Additionally, these models help study resistance mechanisms to mitochondrial-targeted therapies.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, selectively kill cells with a specific mitochondrial mutation. This approach can reveal novel therapeutic targets and biomarkers for patient stratification.